Michael G. King Jr. is a seasoned biotechnology executive and former top-ranked Wall Street analyst with more than three decades of experience spanning equity research, corporate strategy, capital markets, and operating leadership. He is currently Managing Director and Senior Biotechnology Analyst at Rodman and Renshaw where he provides research coverage on biotechnology companies. Prior to Rodman and Renshaw, Michael served as Chief Executive Officer of Oqory Inc., where he led the development of an antibody-drug conjugate (ADC) platform with the potential to address significant unmet needs in oncology. Michael previously served as Chief Financial Officer of SAb Biotherapeutics, a publicly traded biotechnology company advancing a novel, fully human polyclonal antibody platform, including a first-in-class disease-modifying therapy for Type 1 diabetes. His operating experience also includes serving as Senior Vice President of Corporate Development at Ziopharm Oncology, where he was responsible for strategic finance, investor relations, and business development. Earlier in his career, Michael spent more than 25 years as a senior biotechnology equity research analyst, holding Managing Director and leadership roles at firms including Banc of America Securities, Rodman & Renshaw, JMP Securities, HC Wainwright, EF Hutton, and Robertson Stephens. He has been consistently recognized for the depth and originality of his research, earning multiple Institutional Investor and Wall Street Journal rankings, and was a frequent commentator on CNBC, Bloomberg, and in financial media. Across both Wall Street and industry roles, Michael has developed deep domain expertise in oncology, molecular medicine, and metabolic diseases, and has maintained an extensive network of physicians, scientists, investors, and industry executives. His career reflects a rare combination of scientific fluency, capital markets insight, and hands-on leadership in building and financing innovative biotechnology companies.
